Close Menu

Genomic Health

The firm reported that revenues from screening products fell 34 percent year over year, but that it took in $34.6 million in revenues from COVID-19 testing.

New data shows that the test could eventually be useful in helping younger women avoid chemotherapy in the neoadjuvant setting.

The firm reported that revenues from screening products rose 35 percent year over year to nearly $220 million.

The company announced during its Q4 earnings call that it had acquired Paradigm Diagnostics and Viomics to fill out its expertise in cancer diagnostics.

The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 63 percent year over year.

Test volume for its Cologuard test was up 63 percent year over year, while test volume for Genomic Health's Oncotype DX jumped 14 percent.

Such prognostic information could aid clinicians in making decisions about radiotherapy for postmenopausal women with breast cancer.

Investigators compared expression in different men across the genes from three commercial panels, arguing that the findings highlight important unknowns.

While higher recurrence scores have been associated with increased mortality in women, the pattern of the association differed among male patients.

The company reported increase US and international revenues and test volumes, driven by increased adoption and expanding public and private payor coverage.

Pages

Novavax has begun a phase III trial of its SARS-CoV-2 vaccine, according to the New York Times.

Vox reports that the Trump Administration may limit student visas for individuals from some countries to two years.

The governor of New York says the state will conduct its own review of any SARS-CoV-2 vaccine, NPR reports.

This week in Science: Neanderthal Y chromosomes replaced by Homo sapiens Y chromosomes, and more.